APA (7th ed.) Citation

Alderuccio, J. P., Alencar, A. J., Schatz, J. H., Kuker, R. A., Pongas, G., Reis, I. M., . . . Moskowitz, C. H. (2025). Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: A single-centre, single-arm, phase 2 trial. The Lancet. Haematology, 12(1), e23. https://doi.org/10.1016/S2352-3026(24)00345-4

Chicago Style (17th ed.) Citation

Alderuccio, Juan Pablo, et al. "Loncastuximab Tesirine with Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: A Single-centre, Single-arm, Phase 2 Trial." The Lancet. Haematology 12, no. 1 (2025): e23. https://doi.org/10.1016/S2352-3026(24)00345-4.

MLA (9th ed.) Citation

Alderuccio, Juan Pablo, et al. "Loncastuximab Tesirine with Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: A Single-centre, Single-arm, Phase 2 Trial." The Lancet. Haematology, vol. 12, no. 1, 2025, p. e23, https://doi.org/10.1016/S2352-3026(24)00345-4.